ArticleThe American journal of gastroenterology2026
A Comparison of the Predictive Value of 12 Body Composition Markers for Metabolic Dysfunction-Associated Steatotic Liver Disease, At-Risk Metabolic Dysfunction-Associated Steatohepatitis, and Increased Liver Stiffness in a General Population Setting.
Article in The American journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Discordance between adiposity and FIB-4 risk classification in US adults.Journal of diabetes and metabolic disorders · 2026Article
- The dynamic spectrum of steatotic liver disease: the global perspective.Nature reviews. Gastroenterology & hepatology · 2026Review
- Urinary Volatile Organic Compound Metabolites Are Associated With MASLD/MASH in Humans and Induce Steatosis in Liver Organoids.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Association between UMAP-identified body composition phenotypes and metabolic dysfunction-associated steatotic liver disease in the general population of China.Frontiers in nutrition · 2026Article
- Weight Change is Associated With Metabolic Liver Health in a General Population Extending Beyond Weight Loss Targets of International Guidelines.Gastro hep advances · 2026Article
- Adiposity and Metabolic Indices in the Diagnosis and Histological Stage Association of Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionAdipose tissue is a key mediator of metabolic dysfunction-associated steatotic liver disease (MASLD) development and progression into metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Since direct comparisons of body composition parameters are lacking, we here investigate 12 different body composition parameters.
methodsAdult participants from National Health and Nutrition Examination Survey 2017-2023 with liver health data were included. Exclusion criteria were age older than 80 years, excessive alcohol (>60 g/d), viral hepatitis, and missing anthropometrics. MASLD was defined as controlled attenuation parameter ≥275 dB/m with metabolic dysfunction, MASH as FibroScan-aspartate aminotransferase ≥0.35, and increased liver stiffness measurement (LSM) as ≥8 kPa. Predictive performance of 12 body composition parameters was assessed using area under the curve analysis. Predicted probabilities of outcomes were visualized for standardized parameters, and nonlinearity was assessed through restricted cubic splines.
resultsAmong 11,579 participants (age 51 [35-63], 47% male), 41% had MASLD, 6.5% at-risk MASH, and 9.9% increased LSM. Waist circumference (WC) and not BMI or waist-to-height ratio obtained the highest area under the curve for MASLD (0.82), at-risk MASH (0.73), and increased LSM (0.75) outperforming or equaling all other indices across subgroups. Associations between WC and MASLD were nonlinear, with slight risk saturation beyond 100 cm; at-risk MASH was linearly associated across the entire spectrum; and increased LSM risk rose only after WC >100 cm. DISCUSSION: In the general population, MASLD and MASH risk increased even when WC < 100 cm, while increased LSM risk was increasing only >100 cm. Although relatively minor differences, WC consistently demonstrated the highest predictive value for MASLD, at-risk MASH, and increased LSM and therefore most suited for MASLD diagnosis, management, and risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.